Evaluation of the RSR 3 screen ICA™ and 2 screen ICA™ as screening assays for type 1 diabetes in Sweden

Aim The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with newly diagnosed type 1 diabetes (T1D). Methods 3 Screen is designed for combined detection of autoantibodies to glutamic acid decarboxylase...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Acta diabetologica Ročník 59; číslo 6; s. 773 - 781
Hlavní autori:	Törn, Carina, Vaziri-Sani, Fariba, Ramelius, Anita, Elding Larsson, Helena, Ivarsson, Sten Anders, Amoroso, Marie, Furmaniak, Jadwiga, Powell, Michael, Smith, Bernard Rees
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Milan Springer Milan 01.06.2022 Springer Nature B.V
Predmet:	Autoantibodies Autoimmunity Cation Transport Proteins Child Clinical Medicine Diabetes Diabetes mellitus (insulin dependent) Diabetes Mellitus, Type 1 Endocrinology and Diabetes Endokrinologi och diabetes Glutamate Decarboxylase Glutamic acid Humans Insulin Internal Medicine Klinisk medicin Medical and Health Sciences Medicin och hälsovetenskap Medicine Medicine & Public Health Metabolic Diseases Original Original Article Radioimmunoassay Sweden - epidemiology Zinc transporter Sweden IAA Sensitivity Specificity GADA IA-2A ZnT8A
ISSN:	1432-5233, 0940-5429, 1432-5233
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Aim The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with newly diagnosed type 1 diabetes (T1D). Methods 3 Screen is designed for combined detection of autoantibodies to glutamic acid decarboxylase (GADA), to the islet antigen IA-2 (IA-2A) and to zinc transporter 8 (ZnT8A), while 2 Screen detects GADA and IA-2A. Serum samples from 100 T1D patients at onset and 200 healthy controls were studied. Results 3 Screen achieved 93% assay sensitivity and 97.5% specificity, while 2 Screen achieved 91% assay sensitivity and 98.5% specificity. Samples were also tested in assays for individual autoantibodies. There was only one 3 Screen positive healthy control sample (0.5%) that was positive for multiple autoantibodies (IA-2A and ZnT8A). In contrast, most of the 93 3 Screen positive patients were positive for multiple autoantibodies with 72% (67/93) positive for both GADA and IA-2A and 57% (53/93) positive for three autoantibodies (GADA, IA-2A and ZnT8A). Insulin autoantibodies (IAA, measured by radioimmunoassay) were positive in 13 patients and two healthy controls. Conclusion 3 Screen achieved high sensitivity and specificity, suitable for islet cell autoimmunity screening in a healthy population. In the case of 3 Screen positivity, further assays for GADA, IA-2A and ZnT8A are required to check for multiple autoantibody positivity, a hallmark for progression to T1D. In addition, testing for IAA in children below two years of age is warranted.
AbstractList	AimThe study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with newly diagnosed type 1 diabetes (T1D).Methods3 Screen is designed for combined detection of autoantibodies to glutamic acid decarboxylase (GADA), to the islet antigen IA-2 (IA-2A) and to zinc transporter 8 (ZnT8A), while 2 Screen detects GADA and IA-2A. Serum samples from 100 T1D patients at onset and 200 healthy controls were studied.Results3 Screen achieved 93% assay sensitivity and 97.5% specificity, while 2 Screen achieved 91% assay sensitivity and 98.5% specificity. Samples were also tested in assays for individual autoantibodies. There was only one 3 Screen positive healthy control sample (0.5%) that was positive for multiple autoantibodies (IA-2A and ZnT8A). In contrast, most of the 93 3 Screen positive patients were positive for multiple autoantibodies with 72% (67/93) positive for both GADA and IA-2A and 57% (53/93) positive for three autoantibodies (GADA, IA-2A and ZnT8A). Insulin autoantibodies (IAA, measured by radioimmunoassay) were positive in 13 patients and two healthy controls.Conclusion3 Screen achieved high sensitivity and specificity, suitable for islet cell autoimmunity screening in a healthy population. In the case of 3 Screen positivity, further assays for GADA, IA-2A and ZnT8A are required to check for multiple autoantibody positivity, a hallmark for progression to T1D. In addition, testing for IAA in children below two years of age is warranted. Aim The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with newly diagnosed type 1 diabetes (T1D). Methods 3 Screen is designed for combined detection of autoantibodies to glutamic acid decarboxylase (GADA), to the islet antigen IA-2 (IA-2A) and to zinc transporter 8 (ZnT8A), while 2 Screen detects GADA and IA-2A. Serum samples from 100 T1D patients at onset and 200 healthy controls were studied. Results 3 Screen achieved 93% assay sensitivity and 97.5% specificity, while 2 Screen achieved 91% assay sensitivity and 98.5% specificity. Samples were also tested in assays for individual autoantibodies. There was only one 3 Screen positive healthy control sample (0.5%) that was positive for multiple autoantibodies (IA-2A and ZnT8A). In contrast, most of the 93 3 Screen positive patients were positive for multiple autoantibodies with 72% (67/93) positive for both GADA and IA-2A and 57% (53/93) positive for three autoantibodies (GADA, IA-2A and ZnT8A). Insulin autoantibodies (IAA, measured by radioimmunoassay) were positive in 13 patients and two healthy controls. Conclusion 3 Screen achieved high sensitivity and specificity, suitable for islet cell autoimmunity screening in a healthy population. In the case of 3 Screen positivity, further assays for GADA, IA-2A and ZnT8A are required to check for multiple autoantibody positivity, a hallmark for progression to T1D. In addition, testing for IAA in children below two years of age is warranted. Aim: The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with newly diagnosed type 1 diabetes (T1D). Methods: 3 Screen is designed for combined detection of autoantibodies to glutamic acid decarboxylase (GADA), to the islet antigen IA-2 (IA-2A) and to zinc transporter 8 (ZnT8A), while 2 Screen detects GADA and IA-2A. Serum samples from 100 T1D patients at onset and 200 healthy controls were studied. Results: 3 Screen achieved 93% assay sensitivity and 97.5% specificity, while 2 Screen achieved 91% assay sensitivity and 98.5% specificity. Samples were also tested in assays for individual autoantibodies. There was only one 3 Screen positive healthy control sample (0.5%) that was positive for multiple autoantibodies (IA-2A and ZnT8A). In contrast, most of the 93 3 Screen positive patients were positive for multiple autoantibodies with 72% (67/93) positive for both GADA and IA-2A and 57% (53/93) positive for three autoantibodies (GADA, IA-2A and ZnT8A). Insulin autoantibodies (IAA, measured by radioimmunoassay) were positive in 13 patients and two healthy controls. Conclusion: 3 Screen achieved high sensitivity and specificity, suitable for islet cell autoimmunity screening in a healthy population. In the case of 3 Screen positivity, further assays for GADA, IA-2A and ZnT8A are required to check for multiple autoantibody positivity, a hallmark for progression to T1D. In addition, testing for IAA in children below two years of age is warranted. The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with newly diagnosed type 1 diabetes (T1D). 3 Screen is designed for combined detection of autoantibodies to glutamic acid decarboxylase (GADA), to the islet antigen IA-2 (IA-2A) and to zinc transporter 8 (ZnT8A), while 2 Screen detects GADA and IA-2A. Serum samples from 100 T1D patients at onset and 200 healthy controls were studied. 3 Screen achieved 93% assay sensitivity and 97.5% specificity, while 2 Screen achieved 91% assay sensitivity and 98.5% specificity. Samples were also tested in assays for individual autoantibodies. There was only one 3 Screen positive healthy control sample (0.5%) that was positive for multiple autoantibodies (IA-2A and ZnT8A). In contrast, most of the 93 3 Screen positive patients were positive for multiple autoantibodies with 72% (67/93) positive for both GADA and IA-2A and 57% (53/93) positive for three autoantibodies (GADA, IA-2A and ZnT8A). Insulin autoantibodies (IAA, measured by radioimmunoassay) were positive in 13 patients and two healthy controls. 3 Screen achieved high sensitivity and specificity, suitable for islet cell autoimmunity screening in a healthy population. In the case of 3 Screen positivity, further assays for GADA, IA-2A and ZnT8A are required to check for multiple autoantibody positivity, a hallmark for progression to T1D. In addition, testing for IAA in children below two years of age is warranted. The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with newly diagnosed type 1 diabetes (T1D).AIMThe study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with newly diagnosed type 1 diabetes (T1D).3 Screen is designed for combined detection of autoantibodies to glutamic acid decarboxylase (GADA), to the islet antigen IA-2 (IA-2A) and to zinc transporter 8 (ZnT8A), while 2 Screen detects GADA and IA-2A. Serum samples from 100 T1D patients at onset and 200 healthy controls were studied.METHODS3 Screen is designed for combined detection of autoantibodies to glutamic acid decarboxylase (GADA), to the islet antigen IA-2 (IA-2A) and to zinc transporter 8 (ZnT8A), while 2 Screen detects GADA and IA-2A. Serum samples from 100 T1D patients at onset and 200 healthy controls were studied.3 Screen achieved 93% assay sensitivity and 97.5% specificity, while 2 Screen achieved 91% assay sensitivity and 98.5% specificity. Samples were also tested in assays for individual autoantibodies. There was only one 3 Screen positive healthy control sample (0.5%) that was positive for multiple autoantibodies (IA-2A and ZnT8A). In contrast, most of the 93 3 Screen positive patients were positive for multiple autoantibodies with 72% (67/93) positive for both GADA and IA-2A and 57% (53/93) positive for three autoantibodies (GADA, IA-2A and ZnT8A). Insulin autoantibodies (IAA, measured by radioimmunoassay) were positive in 13 patients and two healthy controls.RESULTS3 Screen achieved 93% assay sensitivity and 97.5% specificity, while 2 Screen achieved 91% assay sensitivity and 98.5% specificity. Samples were also tested in assays for individual autoantibodies. There was only one 3 Screen positive healthy control sample (0.5%) that was positive for multiple autoantibodies (IA-2A and ZnT8A). In contrast, most of the 93 3 Screen positive patients were positive for multiple autoantibodies with 72% (67/93) positive for both GADA and IA-2A and 57% (53/93) positive for three autoantibodies (GADA, IA-2A and ZnT8A). Insulin autoantibodies (IAA, measured by radioimmunoassay) were positive in 13 patients and two healthy controls.3 Screen achieved high sensitivity and specificity, suitable for islet cell autoimmunity screening in a healthy population. In the case of 3 Screen positivity, further assays for GADA, IA-2A and ZnT8A are required to check for multiple autoantibody positivity, a hallmark for progression to T1D. In addition, testing for IAA in children below two years of age is warranted.CONCLUSION3 Screen achieved high sensitivity and specificity, suitable for islet cell autoimmunity screening in a healthy population. In the case of 3 Screen positivity, further assays for GADA, IA-2A and ZnT8A are required to check for multiple autoantibody positivity, a hallmark for progression to T1D. In addition, testing for IAA in children below two years of age is warranted.
Author	Furmaniak, Jadwiga Vaziri-Sani, Fariba Amoroso, Marie Elding Larsson, Helena Smith, Bernard Rees Törn, Carina Powell, Michael Ramelius, Anita Ivarsson, Sten Anders
Author_xml	– sequence: 1 givenname: Carina orcidid: 0000-0003-2421-2633 surname: Törn fullname: Törn, Carina email: Carina.Torn@med.lu.se organization: Department of Clinical Sciences, Lund University, Unit for Diabetes and Celiac Disease, Wallenberg Laboratory/CRC – sequence: 2 givenname: Fariba surname: Vaziri-Sani fullname: Vaziri-Sani, Fariba – sequence: 3 givenname: Anita surname: Ramelius fullname: Ramelius, Anita organization: Department of Clinical Sciences, Lund University – sequence: 4 givenname: Helena surname: Elding Larsson fullname: Elding Larsson, Helena organization: Department of Clinical Sciences, Lund University – sequence: 5 givenname: Sten Anders surname: Ivarsson fullname: Ivarsson, Sten Anders organization: Department of Clinical Sciences, Lund University – sequence: 6 givenname: Marie surname: Amoroso fullname: Amoroso, Marie organization: FIRS Laboratories, RSR Ltd – sequence: 7 givenname: Jadwiga surname: Furmaniak fullname: Furmaniak, Jadwiga organization: FIRS Laboratories, RSR Ltd – sequence: 8 givenname: Michael surname: Powell fullname: Powell, Michael organization: FIRS Laboratories, RSR Ltd – sequence: 9 givenname: Bernard Rees surname: Smith fullname: Smith, Bernard Rees organization: FIRS Laboratories, RSR Ltd
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35220476$$D View this record in MEDLINE/PubMed
BookMark	eNp9UstuFDEQHKEg8oAf4IAsceEy4PfMXJBQFAhSJKQEzi2Pp2fXYdZe7JlEe-dL-DS-JN5HINlDDpbtdlV1tbuPiwMfPBbFa0bfM0qrD4lS1fCS8rxYrXSpnhVHTApeKi7EwYPzYXGc0jWljFeiflEcCsU5lZU-Kn6e3ZhhMqMLnoSejHMkl1eXRJBkI6InX08__f39hxjfEb4fS7uA87N8SWaVSB8iGVdLJIx0zrQ4YiLOk6tb7NC_LJ73Zkj4arefFD8-n30_PS8vvn3Jmhel1YKOpaSsq5tOatYwiqy2knEurdCm7xWXtGVMY8UapG3fMdoYo3XLdCbLNhO5OCnMVjfd4nJqYRndwsQVBONgGeJoBoiY0EQ7h2GChJBRg7ObX0hQtVJLWwuwRnCQkreQ5TU0jTQd663RUuUcH7c5MnWBnUU_xqz7KNWjF-_mMAs30NDcKb02-W4nEMOvCdMIC5csDoPxGKYEPJejspFNrrd70OswRZ-_MKM0U6JRUmbUm4eO_lm573UG1FuAjSGliD1YN25qzgbdAIzCeqxgO1aQxwo2YwVrB3yPeq_-JEns2pDBfobxv-0nWHfZn9-y
CitedBy_id	crossref_primary_10_3390_ijms25147618 crossref_primary_10_4239_wjd_v15_i5_935 crossref_primary_10_3389_fendo_2023_1028285
Cites_doi	10.2337/db14-1693 10.1038/347151a0 10.1016/j.cca.2007.10.021 10.1073/pnas.0705894104 10.1016/s0168-8227(99)00008-x 10.2337/dc13-S067 10.1016/S0140-6736(74)90140-8 10.1089/dia.2016.0199 10.1007/s00125-008-0967-2 10.1196/annals.1447.029 10.1007/BF00299026 10.1016/j.cca.2016.08.013 10.1210/jcem.85.12.7070 10.1016/j.jim.2016.01.011 10.1007/s00125-015-3514-y 10.2337/db11-1659 10.2337/db14-1694 10.2337/db08-0522 10.1016/j.jim.2011.06.011 10.2337/diabetes.48.3.460 10.1007/BF00264766 10.1016/0022-1759(95)00139-2 10.4049/jimmunol.155.11.5419 10.2337/dc11-0560 10.1373/clinchem.2019.304196 10.1126/science.6362005
ContentType	Journal Article
Copyright	The Author(s) 2022 2022. The Author(s). The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
CorporateAuthor	Universitetets ledning och förvaltning Cooperation office Research, Collaboration and Innovation Systems Virology Strategiska forskningsområden (SFO) Systemvirologi Medicinska fakulteten Paediatric Endocrinology Universitetsförvaltningen Institutionen för translationell medicin Department of Translational Medicine Central Administration Lunds universitet Profile areas and other strong research environments Department of Clinical Sciences, Malmö University Management and Central Administration Lund University Celiac Disease and Diabetes Unit Lund University Bioimaging Center EXODIAB: Excellence of Diabetes Research in Sweden Faculty of Medicine Celiaki och diabetes Strategic research areas (SRA) LU Samverkan Profilområden och andra starka forskningsmiljöer Sektionen Forskning, samverkan och innovation Pediatrisk endokrinologi Institutionen för kliniska vetenskaper, Malmö
CorporateAuthor_xml	– name: Strategiska forskningsområden (SFO) – name: Celiac Disease and Diabetes Unit – name: Universitetets ledning och förvaltning – name: Strategic research areas (SRA) – name: LU Samverkan – name: Research, Collaboration and Innovation – name: Paediatric Endocrinology – name: Lund University – name: EXODIAB: Excellence of Diabetes Research in Sweden – name: Lund University Bioimaging Center – name: Profile areas and other strong research environments – name: Sektionen Forskning, samverkan och innovation – name: Central Administration – name: Institutionen för translationell medicin – name: Department of Clinical Sciences, Malmö – name: University Management and Central Administration – name: Faculty of Medicine – name: Medicinska fakulteten – name: Celiaki och diabetes – name: Institutionen för kliniska vetenskaper, Malmö – name: Lunds universitet – name: Systems Virology – name: Profilområden och andra starka forskningsmiljöer – name: Cooperation office – name: Systemvirologi – name: Department of Translational Medicine – name: Pediatrisk endokrinologi – name: Universitetsförvaltningen
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 5PM ADTPV AGCHP AOWAS D8T D95 ZZAVC
DOI	10.1007/s00592-022-01856-5
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SWEPUB Lunds universitet full text SwePub Articles SWEPUB Freely available online SWEPUB Lunds universitet SwePub Articles full text
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts MEDLINE - Academic
DatabaseTitleList	AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1432-5233
EndPage	781
ExternalDocumentID	oai_portal_research_lu_se_publications_7b464c83_ca32_442b_b166_994ad1fca645 PMC9085662 35220476 10_1007_s00592_022_01856_5
Genre	Journal Article
GeographicLocations	Sweden
GeographicLocations_xml	– name: Sweden
GrantInformation_xml	– fundername: Lund University – fundername: RSR Ltd – fundername: Lunds Universitet funderid: http://dx.doi.org/10.13039/501100003252 – fundername: ;
GroupedDBID	--- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 199 1N0 2.D 203 23M 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5QI 5VS 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8G5 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSNA ACUDM ACZOJ ADBBV ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DWQXO EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GRRUI GUQSH GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KOV KOW KPH LAS LLZTM M1P M2O M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z7W Z82 Z87 Z8O Z8Q Z8V Z91 ZMTXR ZOVNA ~A9 ~EX 8C1 AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA BBNVY BHPHI CITATION HCIFZ M7P PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 5PM ADTPV AGCHP AOWAS D8T D95 ZZAVC
ID	FETCH-LOGICAL-c630t-401d89d461910e18c41224c36aff5240b116e719e0bfd109aa66b16c634bd8923
IEDL.DBID	RSV
ISICitedReferencesCount	4
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000761862200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1432-5233 0940-5429
IngestDate	Tue Oct 28 03:22:50 EDT 2025 Tue Nov 04 01:35:40 EST 2025 Sat Sep 27 17:16:59 EDT 2025 Tue Oct 07 05:33:32 EDT 2025 Thu Apr 03 07:00:07 EDT 2025 Tue Nov 18 21:34:52 EST 2025 Sat Nov 29 05:03:12 EST 2025 Fri Feb 21 02:47:43 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Keywords	IAA Sensitivity Specificity GADA IA-2A ZnT8A
Language	English
License	2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c630t-401d89d461910e18c41224c36aff5240b116e719e0bfd109aa66b16c634bd8923
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Managed by Antonio Secchi.
ORCID	0000-0003-2421-2633
OpenAccessLink	https://link.springer.com/10.1007/s00592-022-01856-5
PMID	35220476
PQID	2661539544
PQPubID	49275
PageCount	9
ParticipantIDs	swepub_primary_oai_portal_research_lu_se_publications_7b464c83_ca32_442b_b166_994ad1fca645 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9085662 proquest_miscellaneous_2634546445 proquest_journals_2661539544 pubmed_primary_35220476 crossref_citationtrail_10_1007_s00592_022_01856_5 crossref_primary_10_1007_s00592_022_01856_5 springer_journals_10_1007_s00592_022_01856_5
PublicationCentury	2000
PublicationDate	2022-06-01
PublicationDateYYYYMMDD	2022-06-01
PublicationDate_xml	– month: 06 year: 2022 text: 2022-06-01 day: 01
PublicationDecade	2020
PublicationPlace	Milan
PublicationPlace_xml	– name: Milan – name: Germany – name: Heidelberg
PublicationTitle	Acta diabetologica
PublicationTitleAbbrev	Acta Diabetol
PublicationTitleAlternate	Acta Diabetol
PublicationYear	2022
Publisher	Springer Milan Springer Nature B.V
Publisher_xml	– name: Springer Milan – name: Springer Nature B.V
References	Puavilai, Chanprasertyotin, Sriphrapradaeng (CR14) 1999; 44 CR13 CR11 Vaziri-Sani, Delli, Elding-Larsson (CR16) 2011; 371 Bonifacio, Lampasona, Genovese, Ferrari, Bosi (CR4) 1995; 155 Williams, Lampasona, Wyatt (CR22) 2015; 64 Nilson, Ekholm, Rees Smith, Torn, Hillman (CR24) 2008; 88 Delli, Vaziri-Sani, Lindblad (CR17) 2012; 61 Bottazzo, Florin-Christensen, Doniach (CR8) 1974; 2 Wenzlau, Moua, Sarkar (CR5) 2008; 1150 Ziegler, Haupt, Scholz (CR26) 2016; 18 Landin-Olsson, Sundkvist, Lernmark (CR18) 1987; 30 Wenzlau, Juhl, Yu (CR20) 2007; 104 Amoroso, Achenbach, Powell (CR27) 2016; 462 CR2 Williams, Lampasona, Schlosser (CR21) 2015; 64 Rahmati, Lernmark, Becker (CR25) 2008; 49 Zhao, Miao, Michels (CR28) 2016; 430 Christie, Landin-Olsson, Sundkvist, Dahlquist, Lernmark, Baekkeskov (CR3) 1988; 31 Wenzlau, Liu, Yu (CR6) 2008; 57 CR7 Viera, Garrett (CR19) 2005; 37 Ziegler, Hummel, Schenker, Bonifacio (CR10) 1999; 48 Törn, Mueller, Schlosser, Bonifacio, Bingley (CR12) 2008; 51 Hampe, Hammerle, Bekris (CR23) 2000; 85 Krischer, Lynch, Schatz (CR9) 2015; 58 Baekkeskov, Aanstoot, Christgau (CR1) 1990; 347 (CR15) 2013; 36 JP Krischer (1856_CR9) 2015; 58 M Landin-Olsson (1856_CR18) 1987; 30 AG Ziegler (1856_CR26) 2016; 18 AJ Williams (1856_CR21) 2015; 64 AJ Williams (1856_CR22) 2015; 64 JM Wenzlau (1856_CR20) 2007; 104 JM Wenzlau (1856_CR6) 2008; 57 AJ Viera (1856_CR19) 2005; 37 GF Bottazzo (1856_CR8) 1974; 2 1856_CR2 1856_CR11 AJ Delli (1856_CR17) 2012; 61 E Bonifacio (1856_CR4) 1995; 155 American Diabetes Association (1856_CR15) 2013; 36 E Nilson (1856_CR24) 2008; 88 Z Zhao (1856_CR28) 2016; 430 1856_CR13 M Christie (1856_CR3) 1988; 31 C Törn (1856_CR12) 2008; 51 CS Hampe (1856_CR23) 2000; 85 M Amoroso (1856_CR27) 2016; 462 K Rahmati (1856_CR25) 2008; 49 JM Wenzlau (1856_CR5) 2008; 1150 AG Ziegler (1856_CR10) 1999; 48 S Baekkeskov (1856_CR1) 1990; 347 1856_CR7 G Puavilai (1856_CR14) 1999; 44 F Vaziri-Sani (1856_CR16) 2011; 371
References_xml	– volume: 64 start-page: 3239 year: 2015 end-page: 3246 ident: CR21 article-title: Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes publication-title: Diabetes doi: 10.2337/db14-1693 – volume: 347 start-page: 151 year: 1990 end-page: 156 ident: CR1 article-title: Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase publication-title: Nature doi: 10.1038/347151a0 – volume: 88 start-page: 130 year: 2008 end-page: 134 ident: CR24 article-title: Calcium addition to EDTA plasma eliminates falsely positive results in the RSR GADAb ELISA publication-title: Clin Chim Acta doi: 10.1016/j.cca.2007.10.021 – volume: 104 start-page: 17040 year: 2007 end-page: 17045 ident: CR20 article-title: The cation efflux transporter ZnT8 (slc30A8) is a major autoantigen in human type 1 diabetes publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0705894104 – volume: 44 start-page: 21 year: 1999 end-page: 26 ident: CR14 article-title: Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization publication-title: Diabetes Res Clin Pract doi: 10.1016/s0168-8227(99)00008-x – volume: 36 start-page: S67 issue: Suppl 1 year: 2013 end-page: 74 ident: CR15 article-title: Diagnosis and classification of diabetes mellitus publication-title: Diabetes Care doi: 10.2337/dc13-S067 – ident: CR2 – volume: 2 start-page: 1279 year: 1974 end-page: 1283 ident: CR8 article-title: Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies publication-title: Lancet doi: 10.1016/S0140-6736(74)90140-8 – volume: 18 start-page: 687 year: 2016 end-page: 693 ident: CR26 article-title: 3 Screen ELISA for high-throughput detection of beta cell autoantibodies in capillary blood publication-title: Diabetes Technol Ther doi: 10.1089/dia.2016.0199 – volume: 51 start-page: 846 year: 2008 end-page: 852 ident: CR12 article-title: Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2 publication-title: Diabetologia doi: 10.1007/s00125-008-0967-2 – volume: 1150 start-page: 256 year: 2008 end-page: 259 ident: CR5 article-title: SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes publication-title: Ann N Y Acad Sci doi: 10.1196/annals.1447.029 – volume: 30 start-page: 327 year: 1987 end-page: 332 ident: CR18 article-title: Prolonged incubation in the two-colour immunofluorescence test increases the prevalence and titres of islet cell antibodies in Type 1 (insulin-dependent) diabetes mellitus publication-title: Diabetologia doi: 10.1007/BF00299026 – volume: 462 start-page: 60 year: 2016 end-page: 64 ident: CR27 article-title: 3 Screen islet cell autoantibody ELISA: a sensitive and specific ELISA for the combined measurement of autoantibodies to GAD , to IA-2 and to ZnT8 publication-title: Clin Chim Acta doi: 10.1016/j.cca.2016.08.013 – volume: 85 start-page: 4671 year: 2000 end-page: 4679 ident: CR23 article-title: Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.85.12.7070 – volume: 430 start-page: 28 year: 2016 end-page: 32 ident: CR28 article-title: A multiplex assay combining insulin, GAD, IA-2 and transglutaminase autoantibodies to facilitate screening for pre-type 1 diabetes and celiac disease publication-title: J Immunol Methods doi: 10.1016/j.jim.2016.01.011 – volume: 58 start-page: 980 year: 2015 end-page: 987 ident: CR9 article-title: The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study publication-title: Diabetologia doi: 10.1007/s00125-015-3514-y – volume: 155 start-page: 5419 year: 1995 end-page: 5426 ident: CR4 article-title: Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies publication-title: J Immunol – volume: 61 start-page: 2556 year: 2012 end-page: 2564 ident: CR17 article-title: Zinc transporter 8 autoantibodies and their association with SLC30A8 and HLA-DQ genes differ between immigrant and Swedish patients with newly diagnosed type 1 diabetes in the Better Diabetes Diagnosis study publication-title: Diabetes doi: 10.2337/db11-1659 – volume: 64 start-page: 3247 year: 2015 end-page: 3252 ident: CR22 article-title: Reactivity to N-terminally truncated GAD65(96-585) identifies GAD autoantibodies that are more closely associated with diabetes progression in relatives of patients with type 1 diabetes publication-title: Diabetes doi: 10.2337/db14-1694 – volume: 57 start-page: 2693 year: 2008 end-page: 2697 ident: CR6 article-title: A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes publication-title: Diabetes doi: 10.2337/db08-0522 – ident: CR13 – volume: 371 start-page: 25 year: 2011 end-page: 37 ident: CR16 article-title: A novel triple mix radiobinding assay for the three ZnT8 (ZnT8-RWQ) autoantibody variants in children with newly diagnosed diabetes publication-title: J Immunol Methods doi: 10.1016/j.jim.2011.06.011 – ident: CR11 – volume: 48 start-page: 460 year: 1999 end-page: 468 ident: CR10 article-title: Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study publication-title: Diabetes doi: 10.2337/diabetes.48.3.460 – volume: 31 start-page: 597 year: 1988 end-page: 602 ident: CR3 article-title: Antibodies to a Mr-64,000 islet cell protein in Swedish children with newly diagnosed type 1 (insulin-dependent) diabetes publication-title: Diabetologia doi: 10.1007/BF00264766 – ident: CR7 – volume: 49 start-page: 1 year: 2008 end-page: 10 ident: CR25 article-title: A comparison of serum and EDTA-plasma in the measurement of glutamic acid decarboxylase autoantibodies (GADA) and autoantibodies to islet antigen 2 (IA-2A) using the RSR radioimmunoassay (RIA) and enzyme linked immunosorbent assay (ELISA) kits publication-title: Clin Lab – volume: 37 start-page: 360 year: 2005 end-page: 363 ident: CR19 article-title: Understanding interobserver agreement: the kappa statistic publication-title: Fam Med – volume: 51 start-page: 846 year: 2008 ident: 1856_CR12 publication-title: Diabetologia doi: 10.1007/s00125-008-0967-2 – volume: 1150 start-page: 256 year: 2008 ident: 1856_CR5 publication-title: Ann N Y Acad Sci doi: 10.1196/annals.1447.029 – volume: 371 start-page: 25 year: 2011 ident: 1856_CR16 publication-title: J Immunol Methods doi: 10.1016/j.jim.2011.06.011 – volume: 58 start-page: 980 year: 2015 ident: 1856_CR9 publication-title: Diabetologia doi: 10.1007/s00125-015-3514-y – ident: 1856_CR2 doi: 10.1016/0022-1759(95)00139-2 – volume: 347 start-page: 151 year: 1990 ident: 1856_CR1 publication-title: Nature doi: 10.1038/347151a0 – volume: 44 start-page: 21 year: 1999 ident: 1856_CR14 publication-title: Diabetes Res Clin Pract doi: 10.1016/s0168-8227(99)00008-x – volume: 85 start-page: 4671 year: 2000 ident: 1856_CR23 publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.85.12.7070 – volume: 36 start-page: S67 issue: Suppl 1 year: 2013 ident: 1856_CR15 publication-title: Diabetes Care doi: 10.2337/dc13-S067 – volume: 64 start-page: 3247 year: 2015 ident: 1856_CR22 publication-title: Diabetes doi: 10.2337/db14-1694 – volume: 30 start-page: 327 year: 1987 ident: 1856_CR18 publication-title: Diabetologia doi: 10.1007/BF00299026 – volume: 37 start-page: 360 year: 2005 ident: 1856_CR19 publication-title: Fam Med – volume: 155 start-page: 5419 year: 1995 ident: 1856_CR4 publication-title: J Immunol doi: 10.4049/jimmunol.155.11.5419 – volume: 88 start-page: 130 year: 2008 ident: 1856_CR24 publication-title: Clin Chim Acta doi: 10.1016/j.cca.2007.10.021 – ident: 1856_CR11 doi: 10.2337/dc11-0560 – volume: 104 start-page: 17040 year: 2007 ident: 1856_CR20 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0705894104 – ident: 1856_CR13 doi: 10.1373/clinchem.2019.304196 – volume: 57 start-page: 2693 year: 2008 ident: 1856_CR6 publication-title: Diabetes doi: 10.2337/db08-0522 – volume: 64 start-page: 3239 year: 2015 ident: 1856_CR21 publication-title: Diabetes doi: 10.2337/db14-1693 – volume: 430 start-page: 28 year: 2016 ident: 1856_CR28 publication-title: J Immunol Methods doi: 10.1016/j.jim.2016.01.011 – volume: 49 start-page: 1 year: 2008 ident: 1856_CR25 publication-title: Clin Lab – volume: 2 start-page: 1279 year: 1974 ident: 1856_CR8 publication-title: Lancet doi: 10.1016/S0140-6736(74)90140-8 – volume: 61 start-page: 2556 year: 2012 ident: 1856_CR17 publication-title: Diabetes doi: 10.2337/db11-1659 – volume: 31 start-page: 597 year: 1988 ident: 1856_CR3 publication-title: Diabetologia doi: 10.1007/BF00264766 – volume: 48 start-page: 460 year: 1999 ident: 1856_CR10 publication-title: Diabetes doi: 10.2337/diabetes.48.3.460 – volume: 462 start-page: 60 year: 2016 ident: 1856_CR27 publication-title: Clin Chim Acta doi: 10.1016/j.cca.2016.08.013 – ident: 1856_CR7 doi: 10.1126/science.6362005 – volume: 18 start-page: 687 year: 2016 ident: 1856_CR26 publication-title: Diabetes Technol Ther doi: 10.1089/dia.2016.0199
SSID	ssj0012738
Score	2.31988
Snippet	Aim The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients... The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with... AimThe study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with... Aim: The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients...
SourceID	swepub pubmedcentral proquest pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	773
SubjectTerms	Autoantibodies Autoimmunity Cation Transport Proteins Child Clinical Medicine Diabetes Diabetes mellitus (insulin dependent) Diabetes Mellitus, Type 1 Endocrinology and Diabetes Endokrinologi och diabetes Glutamate Decarboxylase Glutamic acid Humans Insulin Internal Medicine Klinisk medicin Medical and Health Sciences Medicin och hälsovetenskap Medicine Medicine & Public Health Metabolic Diseases Original Original Article Radioimmunoassay Sweden - epidemiology Zinc transporter
Title	Evaluation of the RSR 3 screen ICA™ and 2 screen ICA™ as screening assays for type 1 diabetes in Sweden
URI	https://link.springer.com/article/10.1007/s00592-022-01856-5 https://www.ncbi.nlm.nih.gov/pubmed/35220476 https://www.proquest.com/docview/2661539544 https://www.proquest.com/docview/2634546445 https://pubmed.ncbi.nlm.nih.gov/PMC9085662
Volume	59
WOSCitedRecordID	wos000761862200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1432-5233 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0012738 issn: 1432-5233 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7RghAX3o9AqYzEDSLFj9jxsapagQQV2gW04mLZjqOuqLJVswvizi_hp_FLGGcTw7aoEhyTeBLHnrG_8Xg-AzyXSkUiOJU3SodcSEZz673LtWbW1brWNPTs-m_U0VE1m-l3Q1JYN-52H0OS_Uidkt1iniTL4-7zAicZmZdbcBWnuyqa42T6McUOYrLJkB7zd7nNKegCrry4PTLFSM_xifZz0OGt_6v9bbg5YE6yt1aSO3AltHfh-tshqn4PPh8kym-yaAhCQjKZTggnOKSgm0te7-_9_P6D2LYm7Py9briBdcGLzn7rCMJgEld2CSXjyi6Zt2T6NeAYdx8-HB6833-VD4cw5F7yYon-Ja0rXQt0tGgRaOVFjMV5Lm3TlAgHHKUyKKpD4ZqaFtpaKR2VKCwcCjL-ALbbRRseAWGWSlejQOGdiLZfok_MQuCWxVNmdAZ07BfjB4byeFDGiUncyn0rGmxF07eiKTN4kWRO1_wcl5beGbvbDLbamQhRSq5LITJ4lh6jlcXQiW3DYhXLcFEKxI74iodr7UifixC2EEpmoDb0JhWIDN6bT9r5cc_krRHwSskyeDkqze9qXfYXn9ZauPmF3l0zA0fUsTlZmS6Y0z8Wf41y-Au-4sZbzowQzBnsKmm0FramjbdSlI__rS5P4AbrlTquS-3A9vJsFZ7CNf9lOe_OdmFLzard3jx_AZqINGU
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB5BQcCF8k-ggJG4QaTYcez1sapatWK7QrsFVVws23HUFVW2anZB3HkSHq1P0nHWCd0WVYJjYk_s2GP7G4_nM8A7IWUggpNpJZVPuWA0Nc7ZVClmbKlKRX3Lrj-Uo9Hg8FB9ikFhTXfavXNJtjN1H-wW4iRZGk6fZ7jIiLS4Cbc4rljhIN948qX3HYRgkxge83e51SXoCq68ejyy95Fe4hNt16Cd9f-r_QO4HzEn2VwqyUO44etHcGc_etUfw7ftnvKbzCqCkJCMJ2OSE5xS0Mwle1ubZ79-E1OXhF1-18QXWBd8aMzPhiAMJmFnl1DS7eySaU0mPzzOcU_g8872wdZuGi9hSJ3Isznal7QcqJKjoUUzTweOB1-cy4WpqgLhgKVUeEmVz2xV0kwZI4SlAoW5RUGWP4W1elb750CYocKWKJA5y8PYL9AmZt7nhoVbZlQCtOsX7SJDebgo41j33MptK2psRd22oi4SeN_LnCz5Oa7NvdF1t45jtdEBohS5KjhP4G2fjKMsuE5M7WeLkCfnBUfsiJ94ttSOvrgAYTMuRQJyRW_6DIHBezWlnh61TN4KAa8QLIEPndL8qdZ1f_F1qYWrJbTmmo4cUUf6eKEbr08ubP5qafEX3CDXzuRMc86sxq4SWiluSlo5I3jx4t_q8gbu7h7sD_Vwb_TxJdxjrYKHPaoNWJufLvwruO2-z6fN6et2kJ4D0LM2YQ
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BQRWXlndDCxiJG0SNH3HWx6p0RUVZVV1AFRfLdhx1RZVdNbsg7vwSflp_Scd50W1RJcQxjifxY2x_4_F8BngtsywQwWVxkSkfC8lobJyzsVLM2FzlivqaXf8gG40Gx8fq8FIUf33avXNJNjENgaWpnG_P8mK7D3wLMZMsDifRE1xwZJzehjsiXBoU7PXxl96PEAJP2lCZv8stL0fXMOb1o5K9v_QKt2i9Hg3X_78m92GtxaJkp1GeB3DLlw9h9WPrbX8E3_Z6KnAyLQhCRXI0PiKc4FSD5i_Z3905__WbmDIn7Gpa1SZgufChMj8rgvCYhB1fQkm340smJRn_8Dj3PYbPw71Pu-_j9nKG2EmezNHupPlA5QINMJp4OnAi-Ogcl6YoUoQJllLpM6p8YoucJsoYKS2VKCwsCjL-BFbKaek3gDBDpc1RIHFWhDkhRVuZec8NC7fPqAho10fatczl4QKNU91zLtetqLEVdd2KOo3gTS8za3g7bsy91XW9bsdwpQN0SblKhYjgVf8aR19wqZjSTxchDxepQEyJn3jaaEr_uwBtE5HJCLIlHeozBGbv5Tfl5KRm-FYIhKVkEbztFOhPsW6qxddGI5f_UJtxuuWOOtGnC115Pbu0Kawzi1VwA66d4UwLwazGrpJaKWFyWjgjRfrs38ryElYP3w31wf7owybcY7V-h62rLViZny38c7jrvs8n1dmLerxeABTZP0U
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+the+RSR+3+screen+ICA%E2%84%A2+and+2+screen+ICA%E2%84%A2+as+screening+assays+for+type+1+diabetes+in+Sweden&rft.jtitle=Acta+diabetologica&rft.au=T%C3%B6rn%2C+Carina&rft.au=Vaziri-Sani%2C+Fariba&rft.au=Ramelius%2C+Anita&rft.au=Elding+Larsson%2C+Helena&rft.date=2022-06-01&rft.pub=Springer+Milan&rft.eissn=1432-5233&rft.volume=59&rft.issue=6&rft.spage=773&rft.epage=781&rft_id=info:doi/10.1007%2Fs00592-022-01856-5&rft.externalDocID=10_1007_s00592_022_01856_5
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1432-5233&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1432-5233&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1432-5233&client=summon